Core Scientific Holders Poised to Reject CoreWeave Merger, Jefferies Says
The bank said investors are likely to vote down the deal on Oct. 30, betting Core Scientific can create more value on its own.

What to know:
- Jefferies expects Core Scientific shareholders to reject the CoreWeave merger as CORZ trades 18% above the implied offer.
- CORZ can drive value independently with 305 MW of capacity and strong AI data center demand.
- The bank raised its price target to $24 from $22 and reiterated its buy rating on the shares, citing confidence in Core Scientific’s standalone growth potential
Investment bank Jefferies said Core Scientific (CORZ) shareholders appear poised to reject the proposed merger with CoreWeave (CRWV) when they vote on Oct. 30, as CORZ shares are trading roughly 18% above the implied offer price.
The premium suggests investors see the deal as undervaluing Core Scientific, and unless CoreWeave’s stock rallies sharply, Jefferies expects a no outcome, the bank said in a report on Tuesday.
Proxy advisor ISS and major shareholder Two Seas Capital have urged investors to reject the deal, citing valuation concerns and structural flaws.
Core Scientific’s valuation remains complex. Adjusted for land banks and bitcoin
The analysts argued that even if the deal collapses, Core Scientific is well positioned to create value on its own. With 305 megawatts (MW) of billable IT load available, the company could lease capacity to CoreWeave or attract a new hyperscale or “neocloud” tenant, validating its pivot to high-performance computing.
Additional leasing, power expansion, or new site acquisitions could lift its valuation, and Jefferies said a future transition to a REIT model could unlock further upside.
Still, the report cautioned that a failed vote could complicate Core Scientific’s relationship with CoreWeave, potentially making new tenants hesitant to commit. Nonetheless, CoreWeave’s growing demand for GPU capacity could still bring the companies back to the table.
Reflecting its confidence in Core Scientific’s standalone prospects, the bank's analyst raised their price target to $24 from $22.
Core Scientific shares were 1.7% higher in early trading, around $20.44.
Read more: Bitcoin Miner Core Scientific Upgraded to Buy on AI Data Center Boom: H.C. Wainwright
More For You
Protocol Research: GoPlus Security

What to know:
- As of October 2025, GoPlus has generated $4.7M in total revenue across its product lines. The GoPlus App is the primary revenue driver, contributing $2.5M (approx. 53%), followed by the SafeToken Protocol at $1.7M.
- GoPlus Intelligence's Token Security API averaged 717 million monthly calls year-to-date in 2025 , with a peak of nearly 1 billion calls in February 2025. Total blockchain-level requests, including transaction simulations, averaged an additional 350 million per month.
- Since its January 2025 launch , the $GPS token has registered over $5B in total spot volume and $10B in derivatives volume in 2025. Monthly spot volume peaked in March 2025 at over $1.1B , while derivatives volume peaked the same month at over $4B.
More For You
XRP Underperforms Market as Sudden Bitcoin Surge Forces $387M of Liquidations

XRP's technical outlook remains uncertain, with support at $2.05 and resistance at $2.17, as traders watch for volume expansion
What to know:
- XRP posts gains but underperforms compared to the broader digital asset surge, with below-average trading volume raising questions about the move's strength.
- Bitcoin's rise above $94,000 triggered a broad market rebound, leading to significant liquidations and reshuffling of positions.
- XRP's technical outlook remains uncertain, with support at $2.05 and resistance at $2.17, as traders watch for volume expansion to confirm momentum alignment.











